All In Biotech

Drug Trial Radar · NCT07927140

The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)

A Phase 3, Multicenter, Multinational, Randomized, Open-label, Active-comparator Study to Evaluate the Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Dec 11, 2026

Primary completion

Jan 14, 2030

Study completion Mar 3, 2031

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multi-center, multi-national, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat in pediatric (age ≥2 years to ≤11 years) participants with GD3 who have been treated with ERT for at least 2 years, and have met therapeutic goals. Study details include: Study duration: a 52-week primary analysis period and a 52-week extended treatment period. Treatment frequency: * Daily tablets for venglustat for participants randomized to venglustat arm during primary analysis period and for all patients during extended treatment period. * Cerezyme infusion every 2 weeks for participants randomized to Cerezyme arm during primary analysis period and, if needed, as rescue medication for participants in venglustat treated arm during primary analysis period or for any participant during extended treatment period. Visit frequency: every 12 to 14 weeks during primary treatment period and 12-26 weeks during extended treatment period.

Conditions

  • Gaucher's Disease Type III

Interventions

  • VenglustatDrug

    Pharmaceutical form:Tablet-Route of administration:Oral

  • ImigluceraseDrug

    Pharmaceutical form:Sterile lyophilized product vials administered by IV infusion following reconstitution and dilution-Route of administration:IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in magnetic resonance imaging(MRI) spleen volume (in multiples of normal [MN]) at Week 52Time frame: at Week 52

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.